Protagonist Therapeutics, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| PTGX | ROIV | 688177.SS | 688382.SS | IOVA | 8SJ.F | |
|---|---|---|---|---|---|---|
| Market cap | 9.28B | 27.61B | 7.38B | 8.38B | 3.94B | 1.84B |
| P/E (TTM) | 139.2 | — | — | — | — | — |
| Forward P/E | -1,444.4 | -27.5 | -26.2 | -43.8 | -44.4 | — |
| Price/book | 11.0 | 6.5 | 171.3 | 6.6 | 5.4 | 2.4 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +80.07% | +85.85% | −34.43% | −48.70% | +276.62% | −37.59% |
| Today | +2.23% | +6.08% | +2.95% | +4.33% | −1.47% | +1.70% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All PTGX news ›Protagonist Therapeutics: The Opt-Out That Turned A Biotech Into A Royalty Compounder
Protagonist Therapeutics has evolved into a royalty-driven company with two FDA-approved drugs. Read why PTGX stock is a Buy. - Protagonist Therapeutics has evolved into a royalty-driven company with two FDA-approved drugs, robust…
Critical Analysis: Protagonist Therapeutics (NASDAQ:PTGX) & Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT)
Posted by Defense World Staff on Oct 25th, 2026 Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT – Get Free Report) and Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report) are both mid-cap healthcare companies, but…
TD Cowen maintains Buy rating on Protagonist Therapeutics, $160 price target
TradingView TD Cowen maintains Buy rating on Protagonist Therapeutics, $160 price target TD Cowen maintained their Buy rating on Protagonist Therapeutics's stock with a price target of $160.00. The price target implies an
Protagonist Therapeutics (NASDAQ:PTGX) & Sutro Biopharma (NASDAQ:STRO) Financial Review
Posted by Tristan Rich on Oct 20th, 2026 Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report) and Sutro Biopharma (NASDAQ:STRO – Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two…
Analyzing Protagonist Therapeutics (NASDAQ:PTGX) and Sarepta Therapeutics (NASDAQ:SRPT)
Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report) and Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the…
Protagonist Therapeutics (NASDAQ:PTGX) Stock Rating Upgraded by UBS Group
Posted by Tristan Rich on Oct 14th, 2026 Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report) was upgraded by analysts at UBS Group to a “strong-buy” rating in a research report issued to clients and investors on Monday, Zacks reports.…
Protagonist Therapeutics (NASDAQ:PTGX) Stock Keeps "Outperform" Rating at Leerink Partners
MarketBeat Protagonist Therapeutics (NASDAQ:PTGX) Stock Keeps "Outperform" Rating at Leerink Partners - Leerink Partners reaffirmed its “outperform” rating on Protagonist Therapeutics and raised its price tar
Protagonist Therapeutics (NASDAQ:PTGX) Stock Gets Downgrade from Wall Street Zen
Posted by Kim Johansen on Oct 12th, 2026 Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a report issued on Saturday,…
More from 1 other outlet
Reviewing AbCellera Biologics (NASDAQ:ABCL) and Protagonist Therapeutics (NASDAQ:PTGX)
Posted by Defense World Staff on Oct 11th, 2026 Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report) and AbCellera Biologics (NASDAQ:ABCL – Get Free Report) are both mid-cap healthcare companies, but which is the better investment? We…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- defenseworld.net3
- themarketsdaily.com3
- marketbeat.com2
- seekingalpha.com1
- tradingview.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 10 articles, not a forecast.